Uppsala, Sweden, Aug 5, 2026 - Senzime AB (publ), a leader in precision-based perioperative monitoring solutions, today announced that the U.S. Department of Veterans Affairs (VA) Strategic Acquisition Center has awarded a five-year national Non-Expendable Equipment (NX EQ) contract for quantitative neuromuscular monitoring to TrillaMed, LLC, the authorized U.S. federal distributor of the Senzime TetraGraph® system. The contract follows a competitive national procurement process and establishes TetraGraph as the only quantitative neuromuscular monitoring solution currently available through the VA Strategic Acquisition Center's national contracting program.

The contract provides more than 170 VA hospitals and healthcare facilities across the nation's largest integrated healthcare system with streamlined access to Senzime's TetraGraph quantitative neuromuscular monitoring technology through pre-negotiated pricing and a simplified procurement process. Through the VA Strategic Acquisition Center's national contracting program, eligible facilities can rapidly implement evidence-based quantitative neuromuscular monitoring without the need for separate local competitive procurements.

"This national contract award represents another significant milestone for Senzime and reflects the increasing recognition of quantitative neuromuscular monitoring as an essential component of modern anesthesia practice," said Philip Siberg, Chief Executive Officer of Senzime. "Through our partnership with TrillaMed, VA hospitals nationwide will have streamlined access to TetraGraph technology, enabling clinicians to provide Veterans with the highest standard of perioperative care. We believe this agreement will substantially expand the adoption of our technology throughout the VA healthcare system over the next five years."

The U.S. Department of Veterans Affairs serves more than nine million enrolled Veterans in the United States. This national agreement is expected to accelerate the adoption of quantitative neuromuscular monitoring throughout the Veterans Health Administration, further supporting the VA's commitment to delivering the highest standards of perioperative patient care.

The TetraGraph system utilizes electromyography (EMG) technology to deliver objective, quantitative measurements of neuromuscular function before, during, and after the administration of neuromuscular blocking agents and reversals. By providing real-time data, the system helps clinicians optimize timing of intubation, dosing and reversal decisions, supporting evidence-based practice and reducing the risk of residual neuromuscular blockade. TetraGraph is designed to support compliance with recent clinical guidelines published by anesthesiology societies, including the American Society of Anesthesiologists (ASA) and European Society of Anaesthesiology and Intensive Care (ESAIC).

About TrillaMedTrillaMed is a Service-Disabled Veteran-Owned Small Business specializing in delivering innovative medical technologies and healthcare solutions to federal healthcare customers, including the U.S. Department of Veterans Affairs, Department of Defense, and other federal agencies. As Senzime's authorized federal distribution partner, TrillaMed provides procurement strategy, contract administration, sales support, logistics, and customer service throughout the federal healthcare market.

For further information, please contact:

Philip Siberg, CEO of Senzime ABPhone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

About Senzime

Senzime is a leading medical device company at the forefront of a changing healthcare market, driven by new clinical guidelines and emerging technologies. Established in 1999, Senzime develops and markets precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. The flagship solution is the TetraGraph® system, proven best-in-class for accurate monitoring of neuromuscular transmission during surgery and used in thousands of operating rooms across the globe. The system helps to secure precise dosing of paralytic drugs and provides enhanced insights to safeguard every patient's journey, from anesthesia to recovery.

Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the US OTCQX Market (SNZZF), and backed by long-term investors. More information is available at senzime.com.

Attachments

Senzime awarded exclusive 5-year national supply contract with U.S. Veterans Affairs through its partner TrillaMed